Background: Endothelial brokenness and dysregulation of vascular homeostasis are related with diabetic nephropathy (DN). Microalbuminuria (MAU) is a notable indicator of DN in Diabetes Mellitus (DM). Non-dihydropyridine Calcium channel blockers (CCBs) are utilized to diminish proteinuria related with nephropathy in DM patients.
Objective: to detect the early nephropathic changes in diabetic pregnant women and identify the effect of non-dihydropyridine calcium channel blockers, on these changes.
Methodology: Between May 2020 and March 2022, a randomized controlled clinical trial study was conducted at Al-Zahraa University Hospital. Laboratory tests included a complete blood count, fasting blood sugar, and kidney function test (urea, creatinine, Albumin Creatinine Ratio, and urine analysis for MAU) for pregnant women with diabetes mellitus and early DN. For a month, verapamil was taken orally at 80 mg per day.
Results: In patients who have been taking non-dihydropyridine Calcium channel blockers there was a critical decrease in microalbuminuria in contrast with benchmark microalbuminuria, however in the control, no huge change was seen in follow-up microalbuminuria.
Conclusions: after non-dihydropyridine Calcium channel blockers utilization, there was a critical decrease in the degree of albuminuria in contrast with the pre-treatment evaluation.